<DOC>
	<DOCNO>NCT00125645</DOCNO>
	<brief_summary>The purpose study compare change global leave ventricular ( LV ) function 3 month treatment irbesartan compare usual care patient acute myocardial infarction , wall motion score &gt; 1.3 ( EF &gt; 0.40 ) sign diastolic dysfunction . The hypothesis angiotensin 2-receptor inhibitor improve global left ventricular function .</brief_summary>
	<brief_title>Left Ventricular Function After Acute Myocardial Infarction ( AMI ) . Treatment With Angiotensin 2-Receptor Blockade ( GLOBAL-Study )</brief_title>
	<detailed_description>Study objective : Primary Objective : To compare change global LV function assess myocardial performance index ( MPI ) 3 month treatment irbesartan compare usual care patient admit hospital acute myocardial infarction , wall motion score index &gt; 1.3 ( LVEF &gt; 0.40 ) , MPI &gt; 0.55 . Secondary Objectives : - To compare irbesartan add ACE-inhibitor compare usual care patient AMI , WMSI &lt; = 1.3 MPI &gt; 0.55 ; - To compare LV diastolic function assess pulse wave color M-mode Doppler echocardiography leave atrial size treatment irbesartan compare usual care AMI - WMSI &gt; 1.3 MPI &gt; 0.55 ; - WMSI &lt; = 1.3 MPI &gt; 0.55 . - To compare change WMSI treatment irbesartan compare usual care patient AMI - WMSI &gt; 1.3 MPI &gt; 0.55 ; - WMSI &lt; = 1.3 MPI &gt; 0.55 . Tertiary Objectives : To assess effect irbesartan versus usual care neurohormonal activation glucose metabolism ( optional ) . Study Design : A Danish multicenter randomize prospective trial PROBE-design . Study Drug : Patients randomize receive either : irbesartan 300 mg daily usual care . Duration Therapy : Irbesartan 300 mg daily 3 month hospital discharge acute myocardial infarction . Patients receive standard medical therapy include revascularisation appropriate . Expected Number Patients : 200 patient AMI , WMSI &gt; 1.3 MPI &gt; 0.55 ( 100 patient irbesartan group 100 usual care group ) . The patient include analysis primary endpoint . Further , approximately 100 patient AMI , WMSI &lt; = 1.3 MPI &gt; 0.55 treated ACE-inhibitor would part secondary endpoint . Main Inclusion Criteria : - Patients admitted hospital clinical symptom acute myocardial infarction and/or electrocardiographic sign AMI document elevation cardiac marker ( troponin T I ) elevation cardiac enzyme ( creatinine kinase MB ) . - Myocardial performance index ( MPI ) &gt; 0.55 determined echocardiography prior randomization . - Be randomize within 7 day AMI ( patient ) . - Written inform consent Main Exclusion Criteria : - Age &lt; 18 year . - Any contraindication angiotensin 2-receptor blocker . - In patient WMSI &gt; 1.3 treatment ACE-inhibitor angiotensin 2-receptor blocker . - In patient WMSI &lt; = 1.3 initiated plan treatment ACE-inhibitor . Treatment ACE-inhibitor must start within 7 day . - Pregnancy woman childbearing potential use effective method contraception . - Other comorbid condition would influence study . - Currently receive experimental study-drug . Study Medication : Irbesartan 300 mg daily reduce 150 mg discretion treat physician . With dose less 150 mg patient exclude analysis . Mode Administration : The drug give unblinded , blind assessment endpoint . Evaluation Criteria : Primary Outcome : Change MPI patient WMSI &gt; 1.3 treat either irbesartan usual care . Secondary Outcomes : - Change MPI patient WMSI &lt; = 1.3 ACE-inhibitor treat either irbesartan usual care . - Change leave ventricular diastolic function ( pulse wave color M-mode echocardiography leave atrial size ) patient WMSI &gt; 1.3 &lt; = 1.3 . - Change LV systolic function ( WMSI LVEF ) patient WMSI &gt; 1.3 WMSI &lt; = 1.3 . Tertiary Outcomes : Changes neurohormonal activation glucose metabolism ( optional ) . Definitions Objectives : Myocardial Performance Index : MPI calculate sum isovolumetric relaxation contraction time divide ejection time ; measure mitral inflow leave ventricular outflow record obtain pulse wave Doppler echocardiography . LV Diastolic Function : - Assessment mitral inflow curve , E- A-wave deceleration time E-wave . - Color M-mode : Assessment flow propagation velocity . - Left atrial size measure single plane volume four chamber view . Systolic Function : - Wall motion score index : LV divide 16 segment score base myocardial thicken endocardial excursion ( 3 = hyperkinesis , 2 = normokinesis , 1 = hypokinesis , 0 = akinesis -1 = paradoxical motion ) . WMSI calculate divide sum score number segment analyze . - LV ejection fraction obtain multiply WMSI 30 . Neurohormonal activation assess pro-NT-BNP glycemic control assess oral glucose tolerance test hospitalisation 3 month patient without know diabetes mellitus ( optional ) . Statistical Considerations : Population Analyzed : All randomize patient study plan treatment period 3 month , patient &gt; = 150 mg irbesartan analyze accord primary endpoint . Sample Size Consideration : The primary study objective show irbesartan improve MPI usual care 3 month treatment patient AMI , WMSI &gt; 1.3 MPI &gt; 0.55 . Furthermore , patient reduce LV function ( WMSI &lt; = 1.3 ) reduce global LV function ( MPI &gt; 0.55 ) include study irbesartan add ACE-inhibitor compare usual care . This patient include secondary objective therefore sample size estimation perform . 100 patient estimate enrolled study group use descriptive purpose . It assume MPI normal distribution study population previous population patient AMI find , MPIs mean value 0.55 ( SD 0.20 ) patient WMSI &gt; 1.3 ; base estimate change MPI 20 % irbesartan group total approximately 200 patient need study . Duration Treatment Observations : Treatment : Patients receive irbesartan 300 mg daily ( least 150 mg per day ) 3 month treatment . The primary observation period 3 month correspond treatment period , vital status hospitalisation note 6 12 month .</detailed_description>
	<mesh_term>Infarction</mesh_term>
	<mesh_term>Myocardial Infarction</mesh_term>
	<mesh_term>Irbesartan</mesh_term>
	<mesh_term>Angiotensin II</mesh_term>
	<criteria>Documented AMI ; MPI &gt; 0.55 Randomized within 7 day AMI Written inform consent Age &lt; 18 year Any contraindication angiotensin 2receptor blockade In patient WMSI &gt; 1.3 treatment ACEinhibitor angiotensin 2receptor blocker In patient WMSI &lt; = 1.3 initiated plan treatment ACEinhibitor . Treatment ACEinhibitor must start within 7 day Pregnancy woman childbearing potential use effective method contraception Other comorbid condition could influence study Currently receive experimental study drug</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2007</verification_date>
	<keyword>AMI</keyword>
	<keyword>Left ventricular function</keyword>
	<keyword>Myocardial performance index</keyword>
	<keyword>Acute myocardial infarction ( AMI )</keyword>
</DOC>